Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A

Journal of Blood Medicine

Volumn 7, Issue , 2016, Pages 187-198

  Chowdary, Pratima ^a   Fosbury, Emma ^a   Riddell, Anne ^a   Mathias, Mary ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Efraloctocog alfa; Extended half life factors; FVIII; Hemophilia A; Prophylaxis; rFVIIIFc

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8; EFRALOCTOCOG ALFA; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ANNUALIZED BLEED RATE; ARTHRALGIA; ARTICLE; BLEEDING; BLEEDING TIME; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; HEADACHE; HEMARTHROSIS; HEMOPHILIA A; HUMAN; MULTICENTER STUDY (TOPIC); OPERATIVE BLOOD LOSS; PARTIAL THROMBOPLASTIN TIME; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 84992754529     PISSN: None     EISSN: 11792736     Source Type: Journal    
DOI: 10.2147/JBM.S80814     Document Type: Article

References (49)

1. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. 2010; 16(1): 20-32.
2. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med. 2001; 344(23): 1773-1779.
3. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001; 85(3): 560.
4. Lee CA. Front matter. Textbook of Hemophilia. New York, NY: John Wiley and Sons, Ltd; 2014: i-xxi.
5. Reitter S, Waldhoer T, Vutuc C, Lechner K, Pabinger I. Survival in a cohort of patients with haemophilia at the haemophilia care center in Vienna, Austria, from 1983 to 2006. Haemophilia. 2009; 15(4): 888-893.
6. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2001; 7(4): 392-396.
7. George LA, Camire RM. Profile of efraloctocog alfa and its potential in the treatment of hemophilia A. J Blood Med. 2015; 6: 131-141.
8. Thornburg CD. Physicians’ perceptions of adherence to prophylactic clotting factor infusions. Haemophilia. 2008; 14(1): 25-29.
9. Thornburg CD, Carpenter S, Zappa S, Munn J, Leissinger C. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: A survey of haemophilia healthcare professionals in the United States. Haemophilia. 2012; 18(4): 568-574.
10. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011; 22(6): 868-876.
11. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013; 19(1): e1-e47.
12. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012; 379(9824): 1447-1456.
13. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009; 7(3): 413-420.
14. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011; 9(4): 700-710.
15. Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013; 11(6): 1119-1127.
16. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost. 2010; 8(1): 83-89.
17. van den Berg HM, Fischer K, Mauser-Bunschoten EP, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol. 2001; 112(3): 561-565.
18. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992; 232(1): 25-32.
19. Fischer K, Carlsson K, Petrini P, et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood. 2013; 122(7): 1129-1136.
20. Ljung R. Prophylactic therapy in haemophilia. Blood Rev. 2009; 23(6): 267-274.
21. van Creveld S. Prophylaxis in haemophilia. Lancet. 1971; 1(7696): 450.
22. Aledort LM. Prophylaxis: the next haemophilia treatment. J Intern Med. 1992; 232(1): 1-2.
23. Manco-Johnson MJ, Abshire T, Shapiro A, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6): 535-544.
24. Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014; 20(5): 607-615.
25. Den Uijl IEM, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia. 2009; 15(1): 83-90.
26. Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 2012; 119(13): 3024-3030.
27. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7(9): 715-725.
28. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003; 2(3): 214-221.
29. Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release. 2012; 161(2): 461-472.
30. Yatuv R, Robinson M, Dayan-Tarshish I, Baru M. The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia. Int J Nanomedicine. 2010; 5: 581-591.
31. Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: A comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010; 184(4): 1968-1976.
32. Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric factorVIII-Fc fusion protein. J Thromb Haemost. 2013; 11(1): 132-141.
33. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012; 119(13): 3031-3037.
34. Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014; 123(3): 317-325.
35. Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015; 13(6): 967-977.
36. EMEA. European Medicines Agency. Guideline on the Clinical Investigation of Recombinant and Human Plasma-derived Factor VIII Products. London, UK: EMEA; 2011.
37. FDA. Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins. Silver Spring, MD: FDA; 2009.
38. Nestorov I, Neelakantan S, Ludden TM, Li S, Jiang H, Rogge M. Population pharmacokinetics of recombinant factor VIII Fc fusion protein. Clin Pharmacol Drug Dev. 2015; 4(3): 163-174.
39. Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004; 10(5): 428-437.
40. Chalmers EYG, Mahlangu J, Recht M, et al. Treatment of bleeding with recombinant factor VIII FC fusion protein in previously-treated pediatric subjects with hemophilia A in the phase 3 kids a-long study. Paper presented at: XXV Congress of the International Society on Thrombosis and Haemostasis, June 20-25, 2015, Toronto, Canada.
41. FDA. antihemophilic factor [recombinant Fc fusion protein]-FDA Clinical Pharmacology BLA Review. 2013.
42. Nolan B, Mahlangu J, Perry D, et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016; 22(1): 72-80.
43. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia. 2003; 9(4): 418-435.
44. Kitchen S, Gray E, Mertens K. Monitoring of modified factor VIII and IX products. Haemophilia. 2014; 20(Suppl 4): 36-42.
45. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity-assay discrepancies. Haemophilia. 1998; 4(4): 641-645.
46. Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia. 2011; 17(4): 695-702.
47. Ingerslev J, Jankowski MA, Weston SB, Charles LA. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII: C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost. 2004; 2(4): 623-628.
48. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost. 2002; 28(3): 247-256.
49. Sommer JM, Moore N, McGuffie-Valentine B, et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia. 2014; 20(2): 294-300.